- 20/20 GENE SYSTEMS, INC.
- utilizes novel technologies in the development of innovative, proprietary diagnostics for biodefense, cancer and autoimmune diseases.
- 20/20 GeneSystems is developing what we believe will be the first routine blood test for the #1 cancer killer.
- As described in a report published last year in the Journal of Thoracic Oncology 2020's multi-biomarker blood test -- exclusiveiy licensed to us from the University of Kentucky--appears able to detect non-small cell lung cancer (NSCLC) significantly earlier than CT scanning. This builds on work detailed in a 2005 article.
- Other News
-
20/20 Awarded $650K SBIR grant for test to personalize breast cancer therapies
-
20/20 Licences lung cancer test to Ortho-Clinical Diagnostics
-
-
- Oncology
-
• A blood test for the early detection of lung cancer is being developed with Johnson & Johnson. This will be used to screen smokers and former smokers to identify very early signs of lung cancer.
-
• Our patented platform for tumor analysis offers extraordinary advantages for personalizing cancer therapies.
- Biodefense
-
20/20 BioResponse is a profitable business unit of our company selling the BioCheck® screening test kits to emergency responders to screen suspicious powders.